Thrombocytopenia occurs mostly in pregnant women, in which immune thrombocytopenia is believed to be one of the least prevalent forms of thrombocytopenia. Clinical studies indicate that immune thrombocytopenia occurs at a low rate of 11% compared to gestational thrombocytopenia, which occurs at a rate of 59%. However, it is characterized with moderate and severe thrombocytopenia with platelet counts decreasing below 100x109/L. Ordinarily, immune thrombocytopenia is caused by auto-immune reactions against platelets by anti-platelet antibodies, which destroy glycoprotein membranes forming platelet membranes.
Immune thrombocytopenia in pregnancy causes several risks to women and newborns. ITP pregnant women experience high risks of maternal hemorrhage compared to those suffering from other forms of thrombocytopenia. Despite the low percentage of ITP rates in pregnant women, extensive monitoring and management are required, primarily during prenatal care to reduce the risks associated with the disorder.
On the other hand, immune thrombocytopenia in pregnancy presents numerous neonatal concerns. The notion that, immune thrombocytopenia influences delivery alternatives has been disapproved by the recent clinical reports, which are based on randomized clinical trials. In the past, cesarean delivery was considered as a significant obstetric indication in ITP pregnant women. Currently, vaginal birth has been found to reduce trauma in newborns born of ITP mothers.
Moreover, treatment provided to immune thrombocytopenic women prior or during pregnancy causes neonatal concerns. For instance, splenectomy treatment prior to pregnancy has been found to increase free anti-platelet antibodies in maternal circulation, causing a significant risk of anti-platelet reactions in the fetus.
It has also been confirmed that IgG anti-platelet antibodies are transferred from maternal circulation into the fetal body, and this may predispose the fetus to neonatal alloimmune thrombocytopenia (NAIT), leading to neonatal hemorrhage. In conclusion, maternal and neonatal concerns associated with ITP can be reduced through platelet count monitoring during prenatal care.
Table of Contents
1. Immune Thrombocytopenia in Pregnancy
2. Abstract
3. References
Research Objectives and Themes
This paper examines the clinical implications, maternal risks, and neonatal concerns associated with Immune Thrombocytopenia (ITP) during pregnancy, aiming to clarify management strategies and the impact of delivery modes on maternal and fetal health.
- Pathophysiology and classification of thrombocytopenia in pregnant women
- Maternal health risks, specifically the potential for hemorrhage
- Clinical management approaches during the prenatal and post-natal periods
- Evaluation of delivery modes (vaginal vs. cesarean) and their effects on newborns
- Addressing neonatal complications, including alloimmune thrombocytopenia and breastfeeding safety
Excerpt from the Book
IMMUNE THROMBOCYTOPENIA IN PREGNANCY
Thrombocytopenia occurs mostly in pregnant women, and they are characterized by a low platelet count. Platelet levels below 150x109/l are associated with thrombocytopenia. However, thrombocytopenia is classified into three categories in accordance to the associated platelet level count. The main categories are mild, moderate and severe thrombocytopenia. In practice, pregnant women with platelet counts ranging between 100 – 150x109/l are said to be suffering from mild thrombocytopenia while those who record platelet levels ranging between 50 – 100x109/l suffer from moderate thrombocytopenia. Pregnant women whose platelet count decreases below 50x109/l are said to be suffering from severe thrombocytopenia (Kam, Liew & Thompson, 2004).
It has been identified that, thrombocytopenia are caused by decreased platelet production in the patient’s hematopoietic system. The second cause of thrombocytopenia is the accelerated destruction of platelets, primarily through autoimmune reactivity, owing to an autoimmune disorder. This condition has been found to be common in pregnant women with 10 percent of women experiencing thrombocytopenia (Kekomaki et al., 2000).
Summary of Chapters
1. Immune Thrombocytopenia in Pregnancy: This section introduces the clinical definition, classification, and prevalence of thrombocytopenia in pregnant women, highlighting its autoimmune origins.
2. Abstract: A concise overview of the risks, monitoring necessities, and clinical findings regarding maternal and neonatal outcomes related to ITP.
3. References: A comprehensive list of clinical studies, guidelines, and research papers used to analyze ITP management and outcomes.
Keywords
Immune Thrombocytopenia, Pregnancy, Platelet Count, Maternal Hemorrhage, Neonatal Alloimmune Thrombocytopenia, Obstetric Indications, Autoimmune Reactivity, Prenatal Care, Cesarean Delivery, Vaginal Birth, Hematopoietic System, Fetal Health, Post-natal Monitoring
Frequently Asked Questions
What is the primary subject of this research?
The research focuses on Immune Thrombocytopenia (ITP) during pregnancy, covering its clinical manifestations, maternal risks, and the impact on the newborn.
What are the central themes discussed in the paper?
The paper covers the categorization of thrombocytopenia, risks of maternal hemorrhage, the controversy surrounding delivery methods, and potential neonatal complications like alloimmune thrombocytopenia.
What is the primary research goal?
The goal is to analyze clinical data to improve the understanding of ITP management, specifically to clarify if current delivery and treatment practices are optimized for mother and child safety.
Which methodology is applied?
The work utilizes a review of existing clinical research, including randomized clinical trials, retrospective studies, and case studies to evaluate current medical approaches.
What does the main body cover?
It covers the definition of the condition, comparative studies of obstetric outcomes, the evaluation of cesarean vs. vaginal delivery, and the management of neonatal risks like breastfeeding safety.
Which keywords characterize this paper?
Key terms include Immune Thrombocytopenia, maternal hemorrhage, neonatal alloimmune thrombocytopenia (NAIT), platelet count monitoring, and obstetric care.
Does ITP during pregnancy significantly threaten the newborn's life?
Current evidence suggests that while there are risks, most neonates record healthy outcomes, and fatal risks are significantly lower than once believed.
Is a cesarean delivery mandatory for mothers with ITP?
No, recent clinical findings suggest that cesarean delivery should be reserved for standard obstetric indications rather than just the presence of ITP, as there is no clear evidence it prevents bleeding complications.
- Citation du texte
- Patrick Kimuyu (Auteur), 2016, Immune Thrombocytopenia in Pregnancy, Munich, GRIN Verlag, https://www.grin.com/document/381239
